Volume 96 Issue 9 | p. 15 | Concentrates
Issue Date: February 26, 2018

Celularity pursues placental stem cells

By Ryan Cross
Department: Business
Keywords: Biotechnology, Celularity, stem cells, placenta, placental stem cells, Human Longevity, Celgene

Celularity has officially launched with $250 million in funding to develop treatments for cancer, autoimmune disease, diabetes, and even aging, all from placenta-derived stem cells. These stem cells, unlike blood stem cells, do not need to be matched to a patient’s immune system, making them an attractive option for use in many areas of medicine, including CAR-T immunotherapy and regenerative medicine.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment